力达霉素抗肿瘤作用及其分子机制研究新进展

Recent progresses in molecular mechanisms and antitumor activities of lidamycin

力达霉素属于烯二炔类抗肿瘤抗生素,由一个酸性蛋白和一个烯二炔发色团通过非共价键结合而成,通过多种作用机制在体内外对多种肿瘤产生强烈的抗肿瘤作用。目前,力达霉素已经进入Ⅱ期临床研究,本文介绍了力达霉素的抗肿瘤作用和分子作用机制方面的新进展,为进一步研究力达霉素提供参考。

Lidamycin, a member of the enediyne anticancer antibiotics family, is composed of chromophore and apoprotein with noncovalent binding. It exerts potent antitumor activities on a variety of cancer in vitro and in vivo by different mechanisms. Lidamycin is currently evaluated in Phase II clinical trials. In this review we discussed recent progresses in molecular mechanisms and antitumor activities of lidamycin.